Measurement of agouti-related peptide and myeloperoxidase levels and assessment of their potential role in the metabolic pathways of obese individuals with type 2 diabetes
Loading...
EJTCM_2026_9_1_Lateef.pdf (751.68 KB)
0009-0008-3381-8980 Date
2026-06-19
Journal Title
Journal ISSN
Volume Title
Publisher
Gdański Uniwersytet Medyczny
Abstract
Background: Agouti-related peptide (AgRP) and myeloperoxidase (MPO) are key markers associated with metabolic and inflammatory dysfunctions linked to type 2 diabetes (T2DM) and obesity through appetite-regulating mechanisms and immune activity. Material and methods: Total of 150 participants (30-55 years old) were separated into 3 groups: control group, the obesity group, and the T2DM with obesity group. Fasting blood samples were collected. Biochemical tests (e.g. fasting glycemia and lipid profile), were determined using colorimetric methods, while insulin, AgRP, and MPO were measured using ELISA. Statistical analyses (e.g. one-way ANOVA, multiple linear regression, ROC analysis) were conducted. Results: AgRP was significantly higher in the obesity and T2DM with obesity groups. Conversely, MPO levels significantly decreased in these groups (p < 0.0001) compared to the control group. The ROC curve showed good discriminatory performance between patient and control groups. Conclusions: Increased AgRP levels might reflect alterations of appetite and energy balance, while decreased MPO levels may indicate a complex inflammatory response that could involve enzyme retention in certain tissues. This study confirmed the importance of AgRP and MPO as potential supplementary indicators of metabolic disorders. There is a need for more studies to elucidate the mechanisms underlying the decrease in MPO in these patients.
Description
Keywords
Citation
Lateef N D, Khaleel F M. Measurement of agouti-related peptide and myeloperoxidase levels and assessment of their potential role in the metabolic pathways of obese individuals with type 2 diabetes. Eur J Transl Clin Med. 2026;9(1):11-19